Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in May 2016 on request of the Sponsor.
On 2 April 2008, orphan designation (EU/3/08/538) was granted by the European Commission to Pharmion Ltd, United Kingdom, for amrubicin hydrochloride for the treatment of small-cell lung cancer.
The sponsorship was transferred to Celgene Europe Limited, United Kingdom, in December 2008.
|Disease / condition||
Treatment of small cell lung cancer
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.